Close Menu

NEW YORK – BioMérieux said on Thursday that its first quarter 2020 revenues grew almost 22 percent year over year driven by "unprecedented demand" for molecular biology products for use in COVID-19 testing.

For the three months ended April 16, the Marcy l'Étoile, France-based in vitro diagnostics firm reported sales of €769 million ($836.6 million) compared to €632 million a year ago.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.